Pharmaceutical combinations of organo-arsenoxide compounds and mTOR inhibitors

A method of treating a cellular proliferative disease in a vertebrate, the method comprising administering to the vertebrate a therapeutically effective amount of an organo-arsenoxide compound or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor, or a pharmaceutically acceptable salt thereof, wherein the organo-arsenoxide compound, or the pharmaceutically acceptable salt thereof, is administered first, followed by the mTOR inhibitor, or the pharmaceutically acceptable salt thereof, wherein the organo-arsenoxide compound is 4-(N—(S-penicillaminylacetyl)amino)phenylarsinous acid (PENAO), or a pharmaceutically acceptable salt thereof, and the mTOR inhibitor is a rapalog.